- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2021-005245-32 | Sponsor Protocol Number: CF102-212LD | Start Date: 2023-05-09 | |||||||||||
Sponsor Name: CanFite BioPharma Ltd. | |||||||||||||
Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003526-50 | Sponsor Protocol Number: HACOL-ACS | Start Date: 2023-05-09 | ||||||||||||||||
Sponsor Name: Hannover Medical School | ||||||||||||||||||
Full Title: A prospective, interventional, single-center, single-arm study to assess the effectiveness of Bempedoic acid to achieve LDL-cholesterol targets in patients following ST-elevation or Non-ST-elevatio... | ||||||||||||||||||
Medical condition: Patients following acute percutaneous coronary intervention for STEMI or NSTEMI insufficiently treated with high-intensity oral lipid lowering therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001771-14 | Sponsor Protocol Number: SRK-015-004 | Start Date: 2023-05-08 | |||||||||||
Sponsor Name: Scholar Rock, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigat... | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) BE (Ongoing) DE (Ongoing) FR (Trial now transitioned) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003289-18 | Sponsor Protocol Number: 219369 | Start Date: 2023-05-08 | ||||||||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer | ||||||||||||||||||
Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Ongoing) NL (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002470-86 | Sponsor Protocol Number: 20190218 | Start Date: 2023-05-08 | ||||||||||||||||
Sponsor Name: Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without... | ||||||||||||||||||
Medical condition: Overweight and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003564-24 | Sponsor Protocol Number: JAB-3312-1003 | Start Date: 2023-05-05 | |||||||||||
Sponsor Name: Jacobio Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P... | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002650-48 | Sponsor Protocol Number: UCDCRC/22/02 | Start Date: 2023-05-05 | |||||||||||
Sponsor Name: University College Dublin | |||||||||||||
Full Title: The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study) | |||||||||||||
Medical condition: pre-heart failure with preserved ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003865-39 | Sponsor Protocol Number: WSG-AM12 | Start Date: 2023-05-04 | ||||||||||||||||
Sponsor Name: Westdeutsche Studiengruppe GmbH | ||||||||||||||||||
Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer | ||||||||||||||||||
Medical condition: HER2+ early breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003951-41 | Sponsor Protocol Number: BFS-AS-40184 | Start Date: 2023-05-04 | ||||||
Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||
Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th... | ||||||||
Medical condition: Asthma | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000033-33 | Sponsor Protocol Number: 83631 | Start Date: 2023-05-03 | |||||||||||||||||||||
Sponsor Name: Maastricht University | |||||||||||||||||||||||
Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance. | |||||||||||||||||||||||
Medical condition: Hereditary fructose intolerance | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |